A Phase 3 interventional study of amg 162 in Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer and Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma, sponsored by Amgen. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-11.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Multiple Myeloma by Amgen — none open to participants now, none under way, none of them phase 3. Multiple Myeloma · Amgen.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 30th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 13th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 43 studies in Multiple Myeloma by Amgen is open now. The open studies under Multiple Myeloma, anywhere →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 16 · Phase 3 11 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 101 across the 40 interventional studies, 705 across the 1 observational. Of the 41 that completed or were terminated, 36 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Multiple Myeloma by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: amg 162
120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
Number of Participants Survived
Time frame: 2 years
Subjects recuited in this open-label extension study were those who were enrolled in the 2 parent (phase 3, randomized, double-blind, active-controlled) studies 20050103 (NCT00321620) or 20050136 (NCT00321464) at sites in the Czech Republic and United Kingdom.
| Milestone | Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W | Denosumab 120 mg Q4W / Denosumab 120 mg Q4W |
|---|---|---|
| Started | 17 | 18 |
| Completed | 5 | 3 |
| Not completed | 12 | 15 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Death | 4 | 6 |
| Withdrew: Disease progression | 2 | 2 |
| Withdrew: Consent withdrawn | 1 | 3 |
| Withdrew: Administrative decision | 3 | 1 |
| Withdrew: Ineligibility determined | 1 | 0 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Poor performance status | 0 | 1 |
| Participants | Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W | Denosumab 120 mg Q4W / Denosumab 120 mg Q4W |
|---|---|---|
| Number of Participants Survived | 13 | 12 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W | — | 8/17 (47.1%) | 13/17 (76.5%) |
| Denosumab 120 mg Q4W / Denosumab 120 mg Q4W | — | 10/18 (55.6%) | 13/18 (72.2%) |
| Event | Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W | Denosumab 120 mg Q4W / Denosumab 120 mg Q4W |
|---|---|---|
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 2/17 | 1/18 |
| CachexiaMetabolism and nutrition disorders | 1/17 | 2/18 |
| Atrial fibrillationCardiac disorders | 1/17 | 0/18 |
| Cardiac failureCardiac disorders | 1/17 | 0/18 |
| DeathGeneral disorders | 1/17 | 0/18 |
| ConvulsionNervous system disorders | 1/17 | 0/18 |
| Hip arthroplastySurgical and medical procedures | 1/17 | 0/18 |
| Jugular vein thrombosisVascular disorders | 1/17 | 0/18 |
| AnaemiaBlood and lymphatic system disorders | 0/17 | 1/18 |
| DiarrhoeaGastrointestinal disorders | 0/17 | 1/18 |
| Event | Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W | Denosumab 120 mg Q4W / Denosumab 120 mg Q4W |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/17 | 6/18 |
| FatigueGeneral disorders | 3/17 | 6/18 |
| NauseaGastrointestinal disorders | 1/17 | 5/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/17 | 0/18 |
| ConstipationGastrointestinal disorders | 0/17 | 4/18 |
| Decreased appetiteMetabolism and nutrition disorders | 1/17 | 4/18 |
| Back painMusculoskeletal and connective tissue disorders | 2/17 | 4/18 |
| NeutropeniaBlood and lymphatic system disorders | 3/17 | 1/18 |
| Bone painMusculoskeletal and connective tissue disorders | 3/17 | 2/18 |
| VomitingGastrointestinal disorders | 2/17 | 3/18 |
| Age, Continuous(Years) | Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W | Denosumab 120 mg Q4W / Denosumab 120 mg Q4W | Total |
|---|---|---|---|
| Mean | 61.6 ± 11.1 | 61.1 ± 13.0 | 61.3 ± 11.9 |
| Sex: Female, Male(Participants) | Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W | Denosumab 120 mg Q4W / Denosumab 120 mg Q4W | Total |
|---|---|---|---|
| Female | 7 | 6 | 13 |
| Male | 10 | 12 | 22 |
| Race/Ethnicity, Customized(Participants) | Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W | Denosumab 120 mg Q4W / Denosumab 120 mg Q4W | Total |
|---|---|---|---|
| White or Caucasian | 17 | 17 | 34 |
| Black or African American | 0 | 1 | 1 |
The record gives a start of Jul 2009, a primary completion of Feb 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab